Treatment approaches for primary CNS lymphomas

Bibliography

• Reni M, Ferreri AJ, Garancini MP, Villa E. Therapeutic management of primary central nervous system lymphoma in immunocompetent patients: results of a critical review of the literature. Ann Oncol 1997;8:227-34
   PubMed Web of Science ®Google Scholar
• Ferreri AJ, Crocchiolo R, Assanelli A, High-dose chemotherapy supported by autologous stem cell transplantation in patients with primary central nervous system lymphoma: facts and opinions. Leuk lymphoma 2008;49(11):2042-7
   Google Scholar
• Mead GM, Bleehen NM, Gregor A, A medical research council randomized trial in patients with primary cerebral non-Hodgkin lymphoma: cerebral radiotherapy with and without cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy. Cancer. 2000;89:1359-70
   PubMed Web of Science ®Google Scholar
• Ferreri AJ, Reni M, Foppoli M, High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial. Lancet 2009;374:1512-20
   PubMed Web of Science ®Google Scholar
• Morris PG, Abrey LE. Therapeutic challenges in primary CNS lymphoma. Lancet Neurol 2009;8:581-92
   PubMed Web of Science ®Google Scholar
• Nelson DF. Radiotherapy in the treatment of primary central nervous system lymphoma (PCNSL). J Neurooncol 1999;43:241-7
   PubMed Web of Science ®Google Scholar
• DeAngelis LM, Seiferheld W, Schold SC, ; Radiation Therapy Oncology Group Study 93-10. Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: Radiation Therapy Oncology Group Study 93-10. J Clin Oncol 2002;20:4643-8
   PubMed Web of Science ®Google Scholar
• Ferreri AJ, Reni M, Pasini F, A multicenter study of treatment of primary CNS lymphoma. Neurology 2002;58:1513-20
   PubMed Web of Science ®Google Scholar
• Bataille B, Delwail V, Menet E, Primary intracerebral malignant lymphoma: report of 248 cases. J Neurosurg 2000;92:261-6
   PubMed Web of Science ®Google Scholar
• Hayabuchi N, Shibamoto Y, Onizuka Y. Primary central nervous system lymphoma in Japan: a nationwide survey. Int J Radiat Oncol Biol Phys 1999;44:265-72
   PubMed Web of Science ®Google Scholar
• Ferreri AJ, Reni M, Villa E. Therapeutic management of primary central nervous system lymphoma: lessons from prospective trials. Ann Oncol 2000;11:927-37
   PubMed Web of Science ®Google Scholar
• Ferreri AJ, Abrey LE, Blay JY, Summary statement on primary central nervous system lymphomas from the Eighth International Conference on Malignant Lymphoma, Lugano, Switzerland, June 12 to 15, 2002. J Clin Oncol 2003;21:2407-14
   PubMed Web of Science ®Google Scholar
• Shibamoto Y, Hayabuchi N, Hiratsuka J, Is whole-brain irradiation necessary for primary central nervous system lymphoma? Patterns of recurrence after partial-brain irradiation. Cancer 2003;97:128-33
   PubMed Web of Science ®Google Scholar
• Abrey LE, DeAngelis LM, Yahalom J. Long-term survival in primary CNS lymphoma. J Clin Oncol 1998;16:859-63
   PubMed Web of Science ®Google Scholar
• Shah GD, Yahalom J, Correa DD, Combined immunochemotherapy with reduced whole-brain radiotherapy for newly diagnosed primary CNS lymphoma. J Clin Oncol 2007;25:4730-5
   PubMed Web of Science ®Google Scholar
• Abrey LE, Yahalom J, DeAngelis LM. Treatment for primary CNS lymphoma: the next step. J Clin Oncol 2000;18:3144-50
   PubMed Web of Science ®Google Scholar
• Bessell EM, López-Guillermo A, Villá S, Importance of radiotherapy in the outcome of patients with primary CNS lymphoma: an analysis of the CHOD/BVAM regimen followed by two different radiotherapy treatments. J Clin Oncol 2002;20:231-6
   PubMed Web of Science ®Google Scholar
• Glass J, Shustik C, Hochberg FH, Therapy of primary central nervous system lymphoma with pre-irradiation methotrexate, cyclophosphamide, doxorubicin, vincristine, and dexamethasone (MCHOD). J Neurooncol 1996;30:257-65
   PubMed Web of Science ®Google Scholar
• Batchelor T, Carson K, O'Neill A, Treatment of primary CNS lymphoma with methotrexate and deferred radiotherapy: a report of NABTT 96-07. J Clin Oncol 2003;21:1044-9
   PubMed Web of Science ®Google Scholar
• Hoang-Xuan K, Taillandier L, Chinot O, Chemotherapy alone as initial treatment for primary CNS lymphoma in patients older than 60 years: a multicenter phase II study (26952) of the European Organization for Research and Treatment of Cancer Brain Tumor Group. J Clin Oncol 2003;21:2726-31
   PubMed Web of Science ®Google Scholar
• O'Brien P, Roos D, Pratt G, Phase II multicenter study of brief single-agent methotrexate followed by irradiation in primary CNS lymphoma. J Clin Oncol 2000;18:519-26
   PubMed Web of Science ®Google Scholar
• Abrey LE, Moskowitz CH, Mason WP, Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: an intent-to-treat analysis. J Clin Oncol 2003;21:4151-6
   PubMed Web of Science ®Google Scholar
• DeAngelis LM, Yahalom J, Thaler HT, Kher U. Combined modality therapy for primary CNS lymphoma. J Clin Oncol 1992;10:635-43
   PubMed Web of Science ®Google Scholar
• Herrlinger U, Kuker W, Uhl M, NOA-03 trial of high-dose methotrexate in primary central nervous system lymphoma: final report. Ann Neurol 2005;57:843-7
   PubMed Web of Science ®Google Scholar
• Pels H, Schmidt-Wolf IG, Glasmacher A, Primary central nervous system lymphoma: results of a pilot and phase II study of systemic and intraventricular chemotherapy with deferred radiotherapy. J Clin Oncol 2003;21:4489-95
   PubMed Web of Science ®Google Scholar
• Poortmans PM, Kluin-Nelemans HC, Haaxma-Reiche H, High-dose methotrexate-based chemotherapy followed by consolidating radiotherapy in non-AIDS-related primary central nervous system lymphoma: European Organization for Research and Treatment of Cancer Lymphoma Group Phase II Trial 20962. J Clin Oncol 2003;21:4483-8
   PubMed Web of Science ®Google Scholar
• Sandor V, Stark-Vancs V, Pearson D, Phase II trial of chemotherapy alone for primary CNS and intraocular lymphoma. J Clin Oncol 1998;16:3000-6
   PubMed Web of Science ®Google Scholar
• Guha-Thakurta N, Damek D, Pollack C, Hochberg FH. Intravenous methotrexate as initial treatment for primary central nervous system lymphoma: response to therapy and quality of life of patients. J Neurooncol 1999;43:259-68
   PubMed Web of Science ®Google Scholar
• Glass J, Gruber ML, Cher L, Hochberg FH. Preirradiation methotrexate chemotherapy of primary central nervous system lymphoma: long-term outcome. J Neurosurg 1994;81:188-95
   PubMed Web of Science ®Google Scholar
• O'Brien PC, Roos DE, Pratt G, Combined-modality therapy for primary central nervous system lymphoma: long-term data from a Phase II multicenter study (Trans-Tasman Radiation Oncology Group). Int J Radiat Oncol Biol Phys 2006;64:408-13
   PubMed Web of Science ®Google Scholar
• Blay JY, Bouhour D, Carrie C, The C5R protocol: a regimen of high-dose chemotherapy and radiotherapy in primary cerebral non-Hodgkin's lymphoma of patients with no known cause of immunosuppression. Blood 1995;86:2922-9
   PubMed Web of Science ®Google Scholar
• Korfel A, Thiel E. Successful treatment of non-Hodgkin's lymphoma of the central nervous system with BMPD chemotherapy followed by radiotherapy. Leuk Lymphoma 1998;30:609-17
   PubMed Web of Science ®Google Scholar
• Brada M, Hjiyiannakis D, Hines F, Short intensive primary chemotherapy and radiotherapy in sporadic primary CNS lymphoma (PCL). Int J Radiat Oncol Biol Phys 1998;40:1157-62
   PubMed Web of Science ®Google Scholar
• Ferreri AJ, Dell'Oro S, Foppoli M, MATILDE regimen followed by radiotherapy is an active strategy against primary CNS lymphomas. Neurology 2006;66:1435-8
   PubMed Web of Science ®Google Scholar
• Kellie SJ, Barbaric D, Koopmans P, Cerebrospinal fluid concentrations of vincristine after bolus intravenous dosing: a surrogate marker of brain penetration. Cancer 2002;94:1815-20
   PubMed Web of Science ®Google Scholar
• Reni M, Ferreri AJ, Guha-Thakurta N, Clinical relevance of consolidation radiotherapy and other main therapeutic issues in primary central nervous system lymphomas treated with upfront high-dose methotrexate. Int J Radiat Oncol Biol Phys 2001;51:419-25
   PubMed Web of Science ®Google Scholar
• Reni M, Zaja F, Mason W, Temozolomide as salvage treatment in primary brain lymphomas. Br J Cancer 2007;96:864-7
   PubMed Web of Science ®Google Scholar
• Soussain C, Suzan F, Hoang-Xuan K, Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma. J Clin Oncol 2001;19:742-9
   PubMed Web of Science ®Google Scholar
• Soussain C, Hoang-Xuan K, Taillandier L, Intensive chemotherapy followed by hematopoietic stem-cell rescue for refractory and recurrent primary CNS and intraocular lymphoma: Societe Francaise de Greffe de Moelle Osseuse-Therapie Cellulaire. J Clin Oncol 2008;26:2512-18
   PubMed Web of Science ®Google Scholar
• Brevet M, Garidi R, Gruson B, First-line autologous stem cell transplantation in primary CNS lymphoma. Eur J Haematol 2005;75:288-92
   PubMed Web of Science ®Google Scholar
• Colombat P, Lemevel A, Bertrand P, High-dose chemotherapy with autologous stem cell transplantation as first-line therapy for primary CNS lymphoma in patients younger than 60 years: a multicenter phase II study of the GOELAMS group. Bone Marrow Transplant 2006;38:417-20
   PubMed Web of Science ®Google Scholar
• Illerhaus G, Marks R, Ihorst G, High-dose chemotherapy with autologous stem-cell transplantation and hyperfractionated radiotherapy as first-line treatment of primary CNS lymphoma. J Clin Oncol 2006;24:3865-70
   PubMed Web of Science ®Google Scholar
• Illerhaus G, Muller F, Feuerhake F, High-dose chemotherapy and autologous stem-cell transplantation without consolidating radiotherapy as first-line treatment for primary lymphoma of the central nervous system. Haematologica 2008;93:147-8
   PubMed Web of Science ®Google Scholar
• Montemurro M, Kiefer T, Schuler F, Primary central nervous system lymphoma treated with high-dose methotrexate, high-dose busulfan/thiotepa, autologous stem-cell transplantation and response-adapted whole-brain radiotherapy: results of the multicenter Ostdeutsche Studiengruppe Hamato-Onkologie OSHO-53 phase II study. Ann Oncol 2007;18:665-71
   PubMed Web of Science ®Google Scholar
• Cheng T, Forsyth P, Chaudhry A, High-dose thiotepa, busulfan, cyclophosphamide and ASCT without whole-brain radiotherapy for poor prognosis primary CNS lymphoma. Bone Marrow Transplant 2003;31:679-85
   PubMed Web of Science ®Google Scholar
• Coiffier B, Lepage E, Briere J, CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346:235-42
   PubMed Web of Science ®Google Scholar
• Feugier P, Virion JM, Tilly H, Incidence and risk factors for central nervous system occurrence in elderly patients with diffuse large-B-cell lymphoma: influence of rituximab. Ann Oncol 2004;15:129-33
   PubMed Web of Science ®Google Scholar
• Iwamoto FM, Schwartz J, Pandit-Taskar N, Study of radiolabeled indium-111 and yttrium-90 ibritumomab tiuxetan in primary central nervous system lymphoma. Cancer 2007;110:2528-34
   PubMed Web of Science ®Google Scholar
• Doolittle ND, Miner ME, Hall WA, Safety and efficacy of a multicenter study using intraarterial chemotherapy in conjunction with osmotic opening of the blood-brain barrier for the treatment of patients with malignant brain tumors. Cancer 2000;88:637-47
   PubMed Web of Science ®Google Scholar
• Borsi JD, Moe PJ. A comparative study on the pharmacokinetics of methotrexate in a dose range of 0.5 g to 33.6 g/m2 in children with acute lymphoblastic leukemia. Cancer 1987;60:5-13
   PubMed Web of Science ®Google Scholar
• Shapiro WR, Young DF, Mehta BM. Methotrexate: distribution in cerebrospinal fluid after intravenous, ventricular and lumbar injections. N Engl J Med 1975;293:161-6
   PubMed Web of Science ®Google Scholar
• Schultz C, Scott C, Sherman W, Preirradiation chemotherapy with cyclophosphamide, doxorubicin, vincristine, and dexamethasone for primary CNS lymphomas: initial report of radiation therapy oncology group protocol 88-06. J Clin Oncol 1996;14:556-64
   PubMed Web of Science ®Google Scholar
• Ferreri AJ, Reni M, Bolognesi A, Combined therapy for primary central nervous system lymphoma in immunocompetent patients. Eur J Cancer 1995;31A:2008-12
   Google Scholar
• DeAngelis LM. Primary central nervous system lymphoma imitates multiple sclerosis. J Neurooncol 1990;9:177-81
   PubMed Web of Science ®Google Scholar
• Cher L, Glass J, Harsh GR, Hochberg FH. Therapy of primary CNS lymphoma with methotrexate-based chemotherapy and deferred radiotherapy: preliminary results. Neurology 1996;46:1757-9
   PubMed Web of Science ®Google Scholar
• Khan RB, Shi W, Thaler HT, Is intrathecal methotrexate necessary in the treatment of primary CNS lymphoma? J Neurooncol 2002;58:175-8
   PubMed Web of Science ®Google Scholar
• Ferreri AJ, Reni M, Dell'Oro S, Combined treatment with high-dose methotrexate, vincristine and procarbazine, without intrathecal chemotherapy, followed by consolidation radiotherapy for primary central nervous system lymphoma in immunocompetent patients. Oncology 2001;60:134-40
   PubMed Web of Science ®Google Scholar
• Rubenstein JL, Combs D, Rosenberg J, Rituximab therapy for CNS lymphomas: targeting the leptomeningeal compartment. Blood 2003;101:466-8
   PubMed Web of Science ®Google Scholar
• Rubenstein JL, Fridlyand J, Abrey L, Phase I study of intraventricular administration of rituximab in patients with recurrent CNS and intraocular lymphoma. J Clin Oncol 2007;25:1350-6
   PubMed Web of Science ®Google Scholar
• Batchelor TT, Kolak G, Ciordia R, High-dose methotrexate for intraocular lymphoma. Clin Cancer Res 2003;9:711-15
   PubMed Web of Science ®Google Scholar
• Ferreri AJ, Blay JY, Reni M, Relevance of intraocular involvement in the management of primary central nervous system lymphomas. Ann Oncol 2002;13:531-8
   PubMed Web of Science ®Google Scholar
• Grimm SA, Pulido JS, Jahnke K, Primary intraocular lymphoma: an International Primary Central Nervous System Lymphoma Collaborative Group Report. Ann Oncol 2007;18:1851-1855
   PubMed Web of Science ®Google Scholar
• de Smet MD, Vancs VS, Kohler D, Intravitreal chemotherapy for the treatment of recurrent intraocular lymphoma. Br J Ophthalmol 1999;83:448-51
   Google Scholar
• Smith JR, Rosenbaum JT, Wilson DJ, Role of intravitreal methotrexate in the management of primary central nervous system lymphoma with ocular involvement. Ophthalmology 2002;109:1709-16
   PubMed Web of Science ®Google Scholar
• Hottinger AF, DeAngelis LM, Yahalom J, Abrey LE. Salvage whole brain radiotherapy for recurrent or refractory primary CNS lymphoma. Neurology 2007;69:1178-82
   PubMed Web of Science ®Google Scholar
• Nguyen PL, Chakravarti A, Finkelstein DM, Results of whole-brain radiation as salvage of methotrexate failure for immunocompetent patients with primary CNS lymphoma. J Clin Oncol 2005;23:1507-13
   PubMed Web of Science ®Google Scholar
• Arellano-Rodrigo E, Lopez-Guillermo A, Bessell EM, Salvage treatment with etoposide (VP-16), ifosfamide and cytarabine (AraC) for patients with recurrent primary central nervous system lymphoma. Eur J Haematol 2003;70:219-24
   PubMed Web of Science ®Google Scholar
• Enting RH, Demopoulos A, DeAngelis LM, Abrey LE. Salvage therapy for primary CNS lymphoma with a combination of rituximab and temozolomide. Neurology 2004;63:901-3
   PubMed Web of Science ®Google Scholar
• Ruhstaller TW, Amsler U, Cerny T. Rituximab: active treatment of central nervous system involvement by non-Hodgkin's lymphoma? Ann Oncol 2000;11:374-5
   PubMed Web of Science ®Google Scholar
• Panageas SK, Elkin EB, Ben-Porat L, Patterns of treatment in older adults with primary central nervous system lymphoma. Cancer 2007;110:1338-44
   PubMed Web of Science ®Google Scholar
• Batchelor T, Loeffler JS. Primary CNS Lymphoma. J Clin Oncol 2006;24:1281-8
   PubMed Web of Science ®Google Scholar
• Booman M, Szuhai K, Rosenwald A, Genomic alterations and gene expression in primary diffuse large B-cell lymphomas of immune-privileged sites: the importance of apoptosis and immunomodulatory pathways. J Pathol 2008;216:209-17
   PubMed Web of Science ®Google Scholar
• Fischer L, Thiel E, Klasen HA, Prospective trial on topotecan salvage therapy in primary CNS lymphoma. Ann Oncol 2006;17:1141-5
   PubMed Web of Science ®Google Scholar
• Reni M, Mazza E, Foppoli M, Ferreri AJ. Primary central nervous system lymphomas: Salvage treatment after failure to high-dose methotrexate. Cancer Lett 2007;258:165-70
   PubMed Web of Science ®Google Scholar
• Plotkin SR, Betensky RA, Hochberg FH, Treatment of relapsed central nervous system lymphoma with high-dose methotrexate. Clin Cancer Res 2004;10:5643-6
   PubMed Web of Science ®Google Scholar
• Tyson RM, Siegal T, Doolittle ND, Current status and future of relapsed primary central nervous system lymphoma (PCNSL). Leuk Lymphoma 2003;44:627-33
   PubMed Web of Science ®Google Scholar